Elanco Animal Health INC Form 4 insider transactions

Elanco Animal Health Inc.'s CEO, Jeffrey N. Simmons, disposed of 37,898 shares of common stock to cover tax liabilities at a price of $24.88 per share.

Elanco Animal Health Inc. Executive Vice President Timothy J. Bettington reported the disposition of 4,695 common shares at $24.88 per share.

An Elanco Animal Health Inc. executive disposed of 6,492 common shares to cover tax withholding obligations at a price of $24.88 per share.

Elanco Animal Health's Executive Vice President, Jose Manuel Correia de Simas, reported a disposition of 3,371 common shares for tax liability purposes.

Elanco Animal Health's Executive Vice President, Ellen de Brabander, disposed of 8,262 common shares in a pre-planned transaction for tax liability.

An Elanco Animal Health Inc. executive disposed of 3,433 shares of common stock to cover tax liabilities related to equity compensation.

Elanco Animal Health's EVP of Manufacturing and Quality, Grace McArdle, sold 4,322 shares of common stock to cover tax liabilities.

Elanco Animal Health's Chief Accounting Officer, James M. Meer, disposed of 1,389 shares of common stock to cover tax withholding obligations.

Elanco Animal Health's Chief Accounting Officer, James M. Meer, reported the acquisition of common stock and restricted stock units, increasing his beneficial ownership.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, reported significant acquisitions of common stock, restricted stock units, stock options, and deferred stock units.

Elanco Animal Health Inc. Executive Vice President Ramiro Martin Cabral reported significant equity grants and a tax-related disposition of common stock.

Elanco Animal Health Inc's EVP of Manufacturing and Quality, Grace McArdle, reported significant equity grants and option awards, alongside a disposition for tax purposes.

Elanco Animal Health's EVP, David S. Kinard, received significant equity compensation, including restricted stock units and stock options, increasing his beneficial ownership.

Elanco Animal Health's Executive Vice President, Ellen de Brabander, reported new equity grants and a disposition of shares for tax purposes.

Elanco Animal Health Inc.'s Executive Vice President, Timothy J. Bettington, reported significant equity grants and option awards, alongside a tax-related stock disposition, under a pre-arranged trading plan.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, acquired 56.6301 deferred stock units.

Elanco Animal Health CEO Jeffrey N. Simmons acquired 110.8583 deferred stock units, increasing his beneficial ownership.

Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 7.6217 deferred stock units, increasing his beneficial ownership.

Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 7.5552 deferred stock units, increasing his beneficial ownership.

Elanco Animal Health Inc.'s President and CEO, Jeffrey N. Simmons, acquired 109.8905 deferred stock units, increasing his direct beneficial ownership.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, acquired 56.1357 deferred stock units.

Elanco Animal Health CEO Jeffrey N. Simmons acquired 113.4934 deferred stock units, increasing his beneficial ownership to 18,959.0151 units.

Elanco Animal Health's Executive Vice President, Rajeev A. Modi, acquired 57.9762 deferred stock units, increasing his beneficial ownership to 7,538.3256 units.

Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 7.8029 deferred stock units as part of a pre-arranged plan.

Rajeev A. Modi, Elanco's EVP, acquired 60.2735 deferred stock units on January 9, 2026, increasing his direct beneficial ownership.

Elanco Animal Health's EVP and CFO, Robert M. VanHimbergen, acquired 8.1121 deferred stock units under a pre-arranged plan.

Elanco Animal Health CEO Jeffrey N. Simmons acquired 117.9906 deferred stock units on January 9, 2026, increasing his beneficial ownership.

Elanco Animal Health Director Kapila K. Anand deferred cash retainer fees into 381.1312 Deferred Stock Units, increasing her beneficial ownership to 8,894.7414 units.

Elanco Animal Health CEO Jeffrey N. Simmons acquired 122.5327 deferred stock units, increasing his beneficial ownership to 18,727.5311 units.

Elanco Animal Health Executive Vice President Rajeev A. Modi acquired 62.5938 deferred stock units on December 26, 2025.